ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas

Now Viewing

EP: 1.ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas

EP: 2.Emerging Data for Odronextamab in DLBCL

EP: 3.Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas

EP: 4.Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas

EP: 5.ASH 2024 Highlights: Bispecifics in Combination Therapies for B-Cell Lymphomas

EP: 6.MAIC Analyses and Bispecific Therapies: Guiding Treatment Decisions in B-Cell Lymphomas

EP: 7.Understanding CRS and ICANS: Real-World Incidence and Key Patient Risk Factors

EP: 8.Key Strategies for Preventing CRS and ICANS

EP: 9.Step-Up Dosing Protocols and Infection Prevention Strategies for Bispecifics in B-Cell Lymphomas

EP: 10.Overcoming Logistical Hurdles in Bispecific Therapy Implementation

EP: 11.Successful Implementation of Bispecific Therapies: Expert Recommendations

EP: 12.Benefits of Implementing Bispecific Therapies in the Community

EP: 13.Bridging the Gap: Enhancing Communication on Bispecifics Between Academic and Community Centers

EP: 14.Final Thoughts on Bispecifics in B-Cell Lymphomas From ASH 2024

Video content above is prompted by the following:

1. There is a wealth of exciting data emerging from ASH 2024 on bispecific therapies for B-cell lymphomas. Before we discuss these new findings, which bispecific therapies were already available for B-cell lymphomas? How were they typically positioned within treatment algorithms?
2. Let’s discuss some of the long-term data updates being presented. How do the 3-year follow-up data on epcoritamab in DLBCL impact its role in your treatment algorithms?
3. 4-year follow-up data for mosunetuzumab in follicular lymphoma were also presented. What are the key insights from these data?